Development of Fab′ fragments of anti-GD2 immunoliposomes entrapping doxorubicin for experimental therapy of human neuroblastoma

Cancer Letters

Volumn 197, Issue 1-2, 2003, Pages 199-204

  Brignole, Chiara ^a   Marimpietri, Danilo ^a   Gambini, Claudio ^a   Allen, Theresa M ^b   Ponzoni, Mirco ^a   Pastorino, Fabio ^a  

^a G GASLINI INSTITUTE   (Italy)

^b UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Doxorubicin; Fab fragments of anti GD2; Immunoliposomes; Liposomes; Neuroblastoma; Nude mice; Targeted drug delivery; Therapy

Indexed keywords

DISIALOGANGLIOSIDE GD2 MONOCLONAL ANTIBODY; DOXORUBICIN; IMMUNOGLOBULIN F(AB) FRAGMENT; IMMUNOLIPOSOME; UNCLASSIFIED DRUG; ANTINEOPLASTIC ANTIBIOTIC; GANGLIOSIDE; GANGLIOSIDE, GD2; LIPOSOME;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; CANCER CHEMOTHERAPY; CANCER INHIBITION; CANCER SURVIVAL; CELL PROLIFERATION; CONFERENCE PAPER; CONTROLLED STUDY; COVALENT BOND; CYTOTOXICITY; DRUG BINDING; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG FORMULATION; DRUG SCREENING; DRUG TARGETING; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; METASTASIS; MOUSE; NEUROBLASTOMA; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; SURVIVAL TIME; TUMOR CELL LINE; TUMOR XENOGRAFT; XENOGRAFT; ANIMAL; CELL CULTURE; CELL DIVISION; CELL SURVIVAL; IMMUNOLOGY; PATHOLOGY; REVIEW; SURVIVAL RATE;

ANIMALIA; MUS MUSCULUS;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; CELL DIVISION; CELL SURVIVAL; DOXORUBICIN; GANGLIOSIDES; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; LIPOSOMES; MICE; MICE, NUDE; NEUROBLASTOMA; SURVIVAL RATE; TUMOR CELLS, CULTURED;

EID: 0038105280     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0304-3835(03)00099-5     Document Type: Conference Paper

References (19)

1. Ladenstein R., Philip T., Lasset C., Hartmann O., Garaventa A., Pinkerton R., Michon J., Pritchard J., Klingebiel T., Kremens B., Pearson A., Coze C., Paolucci P., Frappaz D., Gadner H., Chauvin F. Multivariate analysis of risk factors in stage 4 neuroblastoma patients over the age of 1 year treated with megatherapy and stem-cell transplantation: a report from the European Bone Marrow Transplantation Solid Tumor Registry. J. Clin. Oncol. 16:1998;953-965.
2. Richardson D.S., Johnson S.A. Anthracyclines in hematology: preclinical studies, toxicity and delivery systems. Blood Rev. 11:1977;201-223.
3. Northfelt D.W., Martin F.J., Working P., Volberding P.A., Russel J., Newman M., Amantea M.A., Kaplan L.D. Doxorubicin encapsulated in liposomes containing surface-bound polyethylene glycol: pharmacokinetics, tumor localization, and safety in patients with AIDS-related Kaposi's sarcoma. J. Clin. Pharmacol. 36:1996;55-63.
4. Muggia F., Hainsworth J.D., Jeffers S., Miller P., Groshen S., Tan M., Roman L., Uziely B., Muderspach L., Garcia A., Burnett A., Greco F.A., Morrow C.P., Paradiso L.J., Liang L.J. Phase II study of liposomal doxorubicin in refractory ovarian cancer: antitumor activity and toxicity modification by liposomal encapsulation. J. Clin. Oncol. 15:1997;987-993.
5. 2. Ann. Oncol. 11:2000;1029-1033.
6. Ahmad I., Allen T.M. Antibody-mediated specific binding and cytotoxicity of liposome-entrapped doxorubicin to lung cancer cells in vitro. Cancer Res. 52:1992;4817-4820.
7. Pastorino F., Stuart D.D., Ponzoni M., Allen T.M. Targeted delivery of antisense oligonucleotides in cancer. J. Controlled Release. 74:2001;69-75.
8. HER2 immunoliposomes for cancer therapy. Proc. Natl. Acad. Sci. USA. 92:1995;1327-1331.
9. Maruyama K., Takahashi N., Tagawa T., Nagaike K., Iwatsuru M. Immunoliposomes bearing polyethyleneglycol-coupled Fab′ fragment show prolonged circulation time and high extravasation into targeted solid tumours in vivo. FEBS Lett. 413:1997;177-180.
10. Sugano M., Egilmez N.K., Yokota S.J., Chen F., Harding J., Huang S.K., Bankert R.B. Antibody targeting of doxorubicin-loaded liposomes suppresses the growth and metastatic spread of established human lung tumor xenografts in severe combined immunodeficient mice. Cancer Res. 60:2000;6942-6949.
11. 2 on human neuroblastoma cells: target antigen for monoclonal antibody-mediated cytolysis and suppression of tumor growth. Cancer Res. 47:1987;1098-1104.
12. Bogenmann E. A metastatic neuroblastoma model in SCID mice. Int. J. Cancer. 67:1996;381-386.
13. Moase E.H., Qi W., Ishida T., Gabos Z., Longenecker B.M., Zimmermann G.L., Ding L., Krantz M., Allen T.M. Anti-MUC-1 immunoliposomal doxorubicin in the treatment of murine models of metastatic breast cancer. Biochim. Biophys. Acta. 77996:2000;1-13.
14. Yu A.L., Uttenreuther-Fischer M.M., Huang C.S., Tsui C.C., Gillies S.D., Reisfeld R.A., Kung F.H. Phase I trial of a human-mouse chimeric anti-disialoganglioside monoclonal antibody ch14.18 in patients with refractory neuroblastoma and osteosarcoma. J. Clin. Oncol. 16:1998;2169-2180.
15. 2-targeted immunoliposomes: antitumor effects. J. Natl. Cancer Inst. 92:2000;253-261.
16. Moss T., Reynolds C.P., Sather H.N., Romansky S.G., Hammond G.D., Seeger R.C. Prognostic value of immunocytologic detection of bone marrow metastases in neuroblastoma. N. Engl. J. Med. 324:1991;219-226.
17. Al-Mehbi A.B., Tozawa K., Fisher A.B., Shienag L., Lee A., Mushel R.J. Intravascular origin of metastasis from the proliferation of endothelium-attached tumor cells: a new model for metastasis. Nat. Med. 6:2000;100-102.
18. Arap W., Pasqualini R., Ruoslahti E. Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model. Science. 279:1998;377-380.
19. 2-mediated melanoma cell targeting and cytotoxicity of liposome-entrapped fenretinide. Int. J. Cancer. 81:1999;268-274.